secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001193125-25-141756
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre reports positive Phase 1 data for SPY002 & SPY072; half-life ~75 days, Phase 2 trials initiated
--------------------------------------------------------------------------------

- SPY002 and SPY072 well tolerated up to 1500 mg; no serious AEs, no TEAEs >Grade 2, no discontinuations.
- SPY002 half-life ~75 days (≥3x first-gen anti-TL1As); supports quarterly or twice-yearly SC dosing.
- Single 100 mg dose of either antibody suppressed free TL1A below LLOQ through 20 weeks.
- SKYLINE-UC (UC) platform trial started May 2025; SKYWAY-RD basket (RA, PsA, axSpA) planned Q3 2025.
- Expects 9 Phase 2 readouts by 2027; cash runway into H2 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312525141756/0001193125-25-141756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312525141756/d18728d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-141756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer